Lloyd Sutherland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lloyd Sutherland has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Antje Timmer
Department of Community Health Sciences, University of Calgary, Calgary, Canada
3 shared publications - Robert J. Hilsden
University of Calgary 1 Calgary, Alberta
3 shared publications Alan Br Thomson
1 shared publicationD C Pearson
Community Health Sciences, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, Canada, T2N 4N1
1 shared publication- David Hailey
University of Wollongong
1 shared publication Eoin A Lalor
1 shared publication
Latest Publications
- Open Access
- 11 February 2003
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 3 (1) , 2
Development and evaluation of a quality score for abstracts
The evaluation of abstracts for scientific meetings has been shown to suffer from poor inter observer reliability. A measure was developed to assess the formal quality of abstract submissions in a standardized way. Item selection was based on scoring systems for full reports, taking into account published guidelines for structured abstracts. Interrater agreement was examined using a random sample of submissions to the American Gastroenterological Association, stratified for research type (n = 100, 1992–1995). For construct validity, the association of formal quality with acceptance for presentation was examined. A questionnaire to expert reviewers evaluated sensibility items, such as ease of use and comprehensiveness. The index comprised 19 items. The summary quality scores showed good interrater agreement (intra class coefficient 0.60 – 0.81). Good abstract quality was associated with abstract acceptance for presentation at the meeting. The instrument was found to be acceptable by expert reviewers. A quality index was developed for the evaluation of scientific meeting abstracts which was shown to be reliable, valid and useful.
- 11 February 2003
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 3 (1) , 2
Open AccessDevelopment and evaluation of a quality score for abstracts
The evaluation of abstracts for scientific meetings has been shown to suffer from poor inter observer reliability. A measure was developed to assess the formal quality of abstract submissions in a standardized way. Item selection was based on scoring systems for full reports, taking into account published guidelines for structured abstracts. Interrater agreement was examined using a random sample of submissions to the American Gastroenterological Association, stratified for research type (n = 100, 1992–1995). For construct validity, the association of formal quality with acceptance for presentation was examined. A questionnaire to expert reviewers evaluated sensibility items, such as ease of use and comprehensiveness. The index comprised 19 items. The summary quality scores showed good interrater agreement (intra class coefficient 0.60 – 0.81). Good abstract quality was associated with abstract acceptance for presentation at the meeting. The instrument was found to be acceptable by expert reviewers. A quality index was developed for the evaluation of scientific meeting abstracts which was shown to be reliable, valid and useful.
- Open Access
- 26 April 2002
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 2 (1) , 7
Publication bias in gastroenterological research – a retrospective cohort study based on abstracts submitted to a scientific meeting
The aim of this study was to examine the determinants of publication and whether publication bias occurred in gastroenterological research. A random sample of abstracts submitted to DDW, the major GI meeting (1992–1995) was evaluated. The publication status was determined by database searches, complemented by a mailed survey to abstract authors. Determinants of publication were examined by Cox proportional hazards model and multiple logistic regression. The sample included abstracts on 326 controlled clinical trials (CCT), 336 other clinical research reports (OCR), and 174 basic science studies (BSS). 392 abstracts (47%) were published as full papers. Acceptance for presentation at the meeting was a strong predictor of subsequent publication for all research types (overall, 54% vs. 34%, OR 2.3, 95% CI 1.7 to 3.1). In the multivariate analysis, multi-center status was found to predict publication (OR 2.8, 95% CI 1.6–4.9). There was no significant association between direction of study results and subsequent publication. Studies were less likely to be published in high impact journals if the results were not statistically significant (OR 0.5, 95 CI 95% 0.3–0.6). The author survey identified lack of time or interest as the main reason for failure to publish. Abstracts which were selected for presentation at the DDW are more likely to be followed by full publications. The statistical significance of the study results was not found to be a predictor of publication but influences the chances for high impact publication.
- 26 April 2002
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 2 (1) , 7
Open AccessPublication bias in gastroenterological research – a retrospective cohort study based on abstracts submitted to a scientific meeting
The aim of this study was to examine the determinants of publication and whether publication bias occurred in gastroenterological research. A random sample of abstracts submitted to DDW, the major GI meeting (1992–1995) was evaluated. The publication status was determined by database searches, complemented by a mailed survey to abstract authors. Determinants of publication were examined by Cox proportional hazards model and multiple logistic regression. The sample included abstracts on 326 controlled clinical trials (CCT), 336 other clinical research reports (OCR), and 174 basic science studies (BSS). 392 abstracts (47%) were published as full papers. Acceptance for presentation at the meeting was a strong predictor of subsequent publication for all research types (overall, 54% vs. 34%, OR 2.3, 95% CI 1.7 to 3.1). In the multivariate analysis, multi-center status was found to predict publication (OR 2.8, 95% CI 1.6–4.9). There was no significant association between direction of study results and subsequent publication. Studies were less likely to be published in high impact journals if the results were not statistically significant (OR 0.5, 95 CI 95% 0.3–0.6). The author survey identified lack of time or interest as the main reason for failure to publish. Abstracts which were selected for presentation at the DDW are more likely to be followed by full publications. The statistical significance of the study results was not found to be a predictor of publication but influences the chances for high impact publication.
- Open Access
- 18 December 2001
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 1 (1) , 13
Determinants of abstract acceptance for the Digestive Diseases Week – a cross sectional study
The Digestive Diseases Week (DDW) is the major meeting for presentation of research in gastroenterology. The acceptance of an abstract for presentation at this meeting is the most important determinant of subsequent full publication. We wished to examine the determinants of abstract acceptance for this meeting. A cross-sectional study was performed, based on abstracts submitted to the DDW. All 17,205 abstracts submitted from 1992 to 1995 were reviewed for acceptance, country of origin and research type (controlled clinical trials (CCT), other clinical research (OCR), basic science (BSS)). A random sub-sample (n = 1,000) was further evaluated for formal abstract quality, statistical significance of study results and sample size. 326 CCT, 455 OCR and 219 BSS abstracts were evaluated in detail. Abstracts from N/W Europe (OR 0.4, 95% CI 0.3–0.6), S/E Europe (OR 0.4, 95% CI 0.2–0.6) and non-Western countries (OR 0.3, 95% CI 0.2–0.5) were less likely to be accepted than North-American contributions when controlling for research type. In addition, the OR for the acceptance for studies with negative results as compared to those with positive results was 0.4 (95% CI 0.3–0.7). A high abstract quality score was also weakly associated with acceptance rates (OR 1.4, 95% CI 1.0–2.0). North-American contributions and reports with statistically positive results have higher acceptance rates at the AGA. Formal abstract quality was also predictive for acceptance.
- 18 December 2001
- Published by Springer Nature in BMC Medical Research Methodology
- Vol. 1 (1) , 13
Open AccessDeterminants of abstract acceptance for the Digestive Diseases Week – a cross sectional study
The Digestive Diseases Week (DDW) is the major meeting for presentation of research in gastroenterology. The acceptance of an abstract for presentation at this meeting is the most important determinant of subsequent full publication. We wished to examine the determinants of abstract acceptance for this meeting. A cross-sectional study was performed, based on abstracts submitted to the DDW. All 17,205 abstracts submitted from 1992 to 1995 were reviewed for acceptance, country of origin and research type (controlled clinical trials (CCT), other clinical research (OCR), basic science (BSS)). A random sub-sample (n = 1,000) was further evaluated for formal abstract quality, statistical significance of study results and sample size. 326 CCT, 455 OCR and 219 BSS abstracts were evaluated in detail. Abstracts from N/W Europe (OR 0.4, 95% CI 0.3–0.6), S/E Europe (OR 0.4, 95% CI 0.2–0.6) and non-Western countries (OR 0.3, 95% CI 0.2–0.5) were less likely to be accepted than North-American contributions when controlling for research type. In addition, the OR for the acceptance for studies with negative results as compared to those with positive results was 0.4 (95% CI 0.3–0.7). A high abstract quality score was also weakly associated with acceptance rates (OR 1.4, 95% CI 1.0–2.0). North-American contributions and reports with statistically positive results have higher acceptance rates at the AGA. Formal abstract quality was also predictive for acceptance.
- 26 October 1998
- Published by Wiley
- No. 2,p. CD000067
Azathioprine for maintenance of remission in Crohn's disease
To assess the effectiveness of azathioprine in maintaining remission of quiescent Crohn's disease. Pertinent studies were selected using the MEDLINE data base (1966 - May 1998), the Cochrane Controlled Trials Register, the Inflammatory Bowel Disease Trials Register, as well as abstracts from major gastrointestinal research meetings and references from published articles and reviews. Five randomized, double-blind, placebo-controlled trials of azathioprine therapy were identified. Two of these trials consisted solely of patients with quiescent Crohn's disease. Three trials had multiple therapeutic arms for both induction of remission and maintenance of remission. Data were extracted by three independent observers (GRM, GF, LRS) based on the intention to treat principle. Peto odds ratios for the overall maintenance of remission, steroid sparing, and withdrawals due to adverse effects were calculated, and from these, 95% confidence intervals were derived. Numbers needed to treat or harm (NNT, NNH respectively) for the maintenance of remission, steroid sparing, and withdrawals due to adverse effects were also determined. Azathioprine had a positive effect on maintaining remission. The Peto odds ratio for maintenance of remission was 2.16 (CI 1.35 - 3.47) with an NNT of 7. A higher dose improved response. A steroid sparing effect was noted, with a Peto odds ratio of 5.22 (CI 1.06 - 25.68) and NNT of 3 for quiescent disease. The Peto odds ratio for withdrawals due to adverse events was 4.36 (CI 1.63 - 11.67), the NNH (Number Needed to Harm) was 19. Azathioprine is effective in maintaining remission. There is evidence for a steroid sparing effect.
- 26 October 1998
- Published by Wiley
- No. 2,p. CD000067
Azathioprine for maintenance of remission in Crohn's disease
To assess the effectiveness of azathioprine in maintaining remission of quiescent Crohn's disease. Pertinent studies were selected using the MEDLINE data base (1966 - May 1998), the Cochrane Controlled Trials Register, the Inflammatory Bowel Disease Trials Register, as well as abstracts from major gastrointestinal research meetings and references from published articles and reviews. Five randomized, double-blind, placebo-controlled trials of azathioprine therapy were identified. Two of these trials consisted solely of patients with quiescent Crohn's disease. Three trials had multiple therapeutic arms for both induction of remission and maintenance of remission. Data were extracted by three independent observers (GRM, GF, LRS) based on the intention to treat principle. Peto odds ratios for the overall maintenance of remission, steroid sparing, and withdrawals due to adverse effects were calculated, and from these, 95% confidence intervals were derived. Numbers needed to treat or harm (NNT, NNH respectively) for the maintenance of remission, steroid sparing, and withdrawals due to adverse effects were also determined. Azathioprine had a positive effect on maintaining remission. The Peto odds ratio for maintenance of remission was 2.16 (CI 1.35 - 3.47) with an NNT of 7. A higher dose improved response. A steroid sparing effect was noted, with a Peto odds ratio of 5.22 (CI 1.06 - 25.68) and NNT of 3 for quiescent disease. The Peto odds ratio for withdrawals due to adverse events was 4.36 (CI 1.63 - 11.67), the NNH (Number Needed to Harm) was 19. Azathioprine is effective in maintaining remission. There is evidence for a steroid sparing effect.
- Open Access
- 1 January 1997
- Published by Hindawi Limited in Canadian Journal of Gastroenterology and Hepatology
- Vol. 11 (3) , 261-264
Maintenance Therapy for Inflammatory Bowel Disease: What Really Works
The propensity of inflammatory bowel disease sufferers to experience recurrent episodes or disease flares is well documented. Until a cure can be found, strategies to lengthen the period of remission offer the greatest opportunity to reduce morbidity and enhance patient quality of life. Therapies that have been shown in randomized, controlled, double-blind clinical trials to either lengthen the time of remission or improve the odds of staying in remission during a set time interval are required.
- 1 January 1997
- Published by Hindawi Limited in Canadian Journal of Gastroenterology and Hepatology
- Vol. 11 (3) , 261-264
Open AccessMaintenance Therapy for Inflammatory Bowel Disease: What Really Works
The propensity of inflammatory bowel disease sufferers to experience recurrent episodes or disease flares is well documented. Until a cure can be found, strategies to lengthen the period of remission offer the greatest opportunity to reduce morbidity and enhance patient quality of life. Therapies that have been shown in randomized, controlled, double-blind clinical trials to either lengthen the time of remission or improve the odds of staying in remission during a set time interval are required.
- Open Access
- 1 January 1997
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 11 (3) , 221-227
Endoscopists’ Opinions of Indications for Upper Gastrointestinal Endoscopy
OBJECTIVE:To determine whether endoscopists and general internistsagreed with the characterization of appropriatenessfor endoscopy of various clinical scenarios, as previouslyreported by the RAND Corporation.DESIGN: Mail survey.STUDY SAMPLE: All endoscopists in western Canadaand a random sample of general internists who did notperform endoscopy.METHODS: Questionnaires were sent to 179 endoscopistsin western Canada who were asked to rate the 53 scenariosfor endoscopy on a nine‐point scale ranging from mostappropriate to most inappropriate. A similar questionnairewas sent to 39 general internists practising in theprovince of Alberta.RESULTS: Response rate was 72% of endoscopists(n=128) and 64% of general internists (n=25). Amongthe endoscopists, there was agreement with the RANDclassification for 32 scenarios. All 18 indicationspreviously thought to be appropriate were consideredto be appropriate. However, endoscopists agreed withonly six of 16 equivocal and eight of 19 indicationsconsidered inappropriate. Discrepancies were reviewedby five experienced endoscopists and most appeared tobe related to a concern regarding possible malignancylinked in part with the definition of failure to respondto medical therapy; and to a refusal to request a bariummeal before endoscopy. Among general internists, therewas agreement with RAND in 26 scenarios. When the appropriatenessrankings of endoscopists and general internists werecompared, there was agreement in 40 of 53 scenarios.Significant discrepancies in ratings were identifiedin scenarios in which barium studies were describedas being normal, known or not done.CONCLUSIONS: The equivocal and inappropriateratings developed by the RAND Corporation are not uniformlyaccepted by the endoscopy community or general internists.Use of the RAND indications for assessing quality assurancecan be challenged.
- 1 January 1997
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 11 (3) , 221-227
Open AccessEndoscopists’ Opinions of Indications for Upper Gastrointestinal Endoscopy
OBJECTIVE:To determine whether endoscopists and general internistsagreed with the characterization of appropriatenessfor endoscopy of various clinical scenarios, as previouslyreported by the RAND Corporation.DESIGN: Mail survey.STUDY SAMPLE: All endoscopists in western Canadaand a random sample of general internists who did notperform endoscopy.METHODS: Questionnaires were sent to 179 endoscopistsin western Canada who were asked to rate the 53 scenariosfor endoscopy on a nine‐point scale ranging from mostappropriate to most inappropriate. A similar questionnairewas sent to 39 general internists practising in theprovince of Alberta.RESULTS: Response rate was 72% of endoscopists(n=128) and 64% of general internists (n=25). Amongthe endoscopists, there was agreement with the RANDclassification for 32 scenarios. All 18 indicationspreviously thought to be appropriate were consideredto be appropriate. However, endoscopists agreed withonly six of 16 equivocal and eight of 19 indicationsconsidered inappropriate. Discrepancies were reviewedby five experienced endoscopists and most appeared tobe related to a concern regarding possible malignancylinked in part with the definition of failure to respondto medical therapy; and to a refusal to request a bariummeal before endoscopy. Among general internists, therewas agreement with RAND in 26 scenarios. When the appropriatenessrankings of endoscopists and general internists werecompared, there was agreement in 40 of 53 scenarios.Significant discrepancies in ratings were identifiedin scenarios in which barium studies were describedas being normal, known or not done.CONCLUSIONS: The equivocal and inappropriateratings developed by the RAND Corporation are not uniformlyaccepted by the endoscopy community or general internists.Use of the RAND indications for assessing quality assurancecan be challenged.
- Open Access
- 1 January 1995
- Published by Hindawi Limited in Canadian Journal of Gastroenterology and Hepatology
- Vol. 9 (7) , 401-404
How to Appraise a Clinical Trial Critically
Most clinicians wish to base their therapeutic decisions on scientific data but are often overwhelmed by the number of case reports, open series and other therapeutic trials published each year. It is essential to develop a personal screening plan that can alert the clinician to which reports deserve extra attention, as they may alter management, and to which reports can be ignored. The first step is to review the Decisions related to therapeutics should be based on randomized, controlled, double-blinded, clinical trials. If these key words are not included in the abstract, it is unlikely that the report will change clinical practice. Each of these terms describes an essential element that attempts to assure that the results of the trial will be unbiased and generally applicable to clinical practice. The next step is to examine the Methods section. Clinicians should be interested in the inclusion and exclusion criteria. Two questions arise. First, do the study participants resemble patients in your practice? Second, how many patients were assessed in order to enrol the study population? If only a few of the patients screened actually entered the trial the results may not be of use for the general population with the disease. Another important screening process is to review the Statistical section. It is not necessary to be a statistician, but one should read the section to determine whether a sample size calculation was performed and whether confidence intervals have been calculated around the major end-points. By remembering these key concepts, clinicians can reduce the number of journal articles they read without compromising their ability to be informed of major breakthroughs in the management of disease.
- 1 January 1995
- Published by Hindawi Limited in Canadian Journal of Gastroenterology and Hepatology
- Vol. 9 (7) , 401-404
Open AccessHow to Appraise a Clinical Trial Critically
Most clinicians wish to base their therapeutic decisions on scientific data but are often overwhelmed by the number of case reports, open series and other therapeutic trials published each year. It is essential to develop a personal screening plan that can alert the clinician to which reports deserve extra attention, as they may alter management, and to which reports can be ignored. The first step is to review the Decisions related to therapeutics should be based on randomized, controlled, double-blinded, clinical trials. If these key words are not included in the abstract, it is unlikely that the report will change clinical practice. Each of these terms describes an essential element that attempts to assure that the results of the trial will be unbiased and generally applicable to clinical practice. The next step is to examine the Methods section. Clinicians should be interested in the inclusion and exclusion criteria. Two questions arise. First, do the study participants resemble patients in your practice? Second, how many patients were assessed in order to enrol the study population? If only a few of the patients screened actually entered the trial the results may not be of use for the general population with the disease. Another important screening process is to review the Statistical section. It is not necessary to be a statistician, but one should read the section to determine whether a sample size calculation was performed and whether confidence intervals have been calculated around the major end-points. By remembering these key concepts, clinicians can reduce the number of journal articles they read without compromising their ability to be informed of major breakthroughs in the management of disease.